MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Written by / Agency / Source: General Electric Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Selects Bionime to Launch Innovative Diabetes Solutions - Bionime will offer innovative GE-branded clinical and home-based patient care products for the rapidly growing global diabetes population (NYSE: GE) - Bionime.com / GEDiabetes.com
GE Selects Bionime to Launch Innovative Diabetes Solutions

 

NewswireToday - /newswire/ - Albany, NY, United States, 2012/01/17 - Bionime will offer innovative GE-branded clinical and home-based patient care products for the rapidly growing global diabetes population (NYSE: GE) - Bionime.com / GEDiabetes.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GE today announced it has entered into a new worldwide licensing agreement with Bionime, a global leader in biotechnology medical testing, to provide new GE-branded solutions for the diabetes market.

According to the World Health Organization, an estimated 346 million people worldwide have diabetes. Type 2 diabetes is the fastest growing chronic disease in the world. Through this agreement, Bionime will deliver GE-branded blood glucose monitors, test strips, kits and related diabetes accessories.

The first product to be launched is the GE100 Blood Glucose Monitoring System, available now through durable medical equipment suppliers and on retail shelves in 2012. The GE100 utilizes advanced patented strip technology to achieve a high level of accuracy and precision and a unique, innovative strip design that makes it easier to use and more sanitary for the consumer than current similar offerings. In addition, patented True Auto Coding Technology eliminates the need to code each strip lot without sacrificing the accuracy of the readings. The GE100 provides an easy, clean and accurate way to test blood glucose levels of people living with diabetes.

“We are very excited to work with Bionime to provide innovative blood glucose monitoring for diabetes patients worldwide,” said David Ataide, General Manager, Strategic & Customer Initiatives, GE Healthcare. “Managing diabetes care is critical to the health of our society, and we believe this an important first step for our business.”

“Bionime’s vision is that with our ‘peace of mind’ medical devices, we offer solutions to patients to accurately manage and control their own health,” noted Roy Huang, Chairman, Bionime Corporation. “By joining forces with GE, we can grow this vision by developing new offerings and widening the market for Bionime’s products.”

For more information on the GE100 Blood Glucose Monitoring System, please visit gediabetes.com/.

About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.

About Bionime
Established in April 2003, BIONIME (bionime.com) is specialized in the business of biotechnology and medical testing. BIONIME integrates top-tier expertise in medical science, chemistry, electronics and precision engineering to commercialize our patented noble metal, biosensor technology used in our meters and test strips. Today, BIONIME employs more than 500 people and operates 4 subsidiaries in Europe, the Americas, Australia and Asia. Our products have been shown to meet or exceed the highest standards of accuracy and precision in numerous independent studies published in leading international clinical journals. Bionime products are distributed worldwide and are available in all the major markets.

Press Contact
Colleen Sabo - GE Licensing
P: 609-936-6112 / E: colleen.sabo[.]ge.com.

Steve Millilo - Bionime
P: (551) 482-2840 / E: Steve.Millilo[.]bionime.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Selects Bionime to Launch Innovative Diabetes Solutions

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Rebecca Hayne - GE Healthcare 
414-248-1542 rebecca.hayne[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health / Surgery Most Recent Related Newswires:

Demand for CROs Rises to Strike Evolving Clinical Trial Models for Target Therapies Reports Frost & Sullivan
PointClickCare Integrated Care Coordination Platform Applauded by Frost & Sullivan
Inkwood Research Publishes Global Genetic Testing Market Forecast 2019-2027
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
Alopecia Hair Loss Treatment Market is Advancing At A CAGR of 5.51% by 2027 According to Inkwood Research
Frost & Sullivan Distinguishes Inovalon as Company of the Year for Advancing the Healthcare Industry by Harnessing Massive-Scale Data
South Carolina Life Sciences Industry Honors USC’s Dr. Harris Pastides, AVX Corporation
Neurodegenerative Disorder Therapeutics Market Sees a Silver Lining with Cell and Gene Therapies Finds Frost & Sullivan
Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs
The Global Postpartum Hemorrhage Treatment Device Market is Estimated to Grow At 5.10% CAGR by 2027 Finds Inkwood Research
Digital Health to Empower Women and Aging Population with mHealth, Telemedicine, Femtech and AI Finds Frost & Sullivan
Technological Advancements Propels the Global Healthcare Analytics Market At 27.13% CAGR by 2027 Reports Inkwood Research
SC Life Sciences Conference to Feature J&J Innovation Leader Michal Preminger, 40 National Speakers
American Well® Applauded by Frost & Sullivan for Driving Telehealth’s Next Growth Wave with its Pioneering Strategy
Liquid Biopsy Applications Drives the Global DNA Sequencing Market At a CAGR of 17.46% by 2027 Finds Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)